Avita Medical, Inc. - Common Stock (RCEL)

Going concern warning removed as revenue jumps and guidance rises again.

Avita Medical (NASDAQ:RCEL) raised its full-year revenue forecast for the second consecutive quarter after third-quarter sales rose 53% from a year earlier, driven by demand for its RECELL wound treatment system and growing adoption of Cohealyx. The company reported revenue of $26.1 million, up fro

Avita Medical (NASDAQ:RCEL) presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness skin grafting, compared with cadaveric allograft. During a key opinion leader webinar, the company

Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from $19.3 million in the first quarter and 18% from $18.4 million a year earlier, as the wound-care company cited growth across its product portfolio and in U.S. and international markets. Presid

Avita Medical (NASDAQ:RCEL) expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025, President and CEO Cary Vance said at the Canaccord 46th Annual Boston Growth Conference. Vance, who has been CEO for about 10 months after previously serving

Revenue exceeded $21.7 million with guidance raised to $86M–$89M for full year.

Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out yesterday.

Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 18% from a year earlier and 13% sequentially, as growth in its RECELL wound-care product and newer portfolio offerings supported results. President and Chief Executive Officer Cary Vance said the company’s U.S. RE

Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics (NASDAQ:LSTA)

Avita (RCEL) Q1 2026 Earnings Call Transcript

Avita Medical (NASDAQ:RCEL) reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook as management said reimbursement conditions for its RECELL product are normalizing and demand patterns are becoming more consistent. The regenerative medicine company posted first-quarter rev

AVITA Medical (RCEL) Q4 2025 Earnings Transcript

AVITA Medical (RCEL) Q3 2025 Earnings Transcript

AVITA Medical's Q3 revenue missed estimates due to reimbursement headwinds, but the company improved cost control and secured key Medicare pricing.

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.